RxDoctor Payments Data

Anthony House, MD

Internal Medicine · Mobile, ALNPI 1952615973

Payments from drug & device makers

$754in general payments, 2019–2025

Across 42 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$142
  • Johnson & Johnson$114
  • Novo Nordisk$96
  • AbbVie$85
  • Pfizer$71
  • Si-bone, Inc.$59
  • plus $187 from 8 others

What the payments were for

  • Food & beverage$754100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$754 in reported general payments places this provider in the 55th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$115,345
Medicare patients
574
Services billed
11,969

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide189$234,251
OzempicSemaglutide221$224,286
EliquisApixaban245$165,873
FarxigaDapagliflozin Propanediol148$128,579
LinzessLinaclotide78$67,306
Trelegy ElliptaFluticasone/Umeclidin/Vilanter69$54,513
JanuviaSitagliptin Phosphate48$54,379
JardianceEmpagliflozin93$51,708
XareltoRivaroxaban49$42,321
TrulicityDulaglutide29$39,519
RybelsusSemaglutide19$26,286
Tresiba Flextouch U-100Insulin Degludec42$21,017
Lantus SolostarInsulin Glargine,hum.Rec.Anlog153$19,156
Breo ElliptaFluticasone/Vilanterol41$17,633
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr34$17,387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30$11$279,593261 claims
Novo NordiskOzempic, Rybelsus$96$250,572240 claims
PfizerEliquis$71$165,873245 claims
AbbVieLinzess$85$67,30678 claims
Johnson & JohnsonXarelto$114$42,32149 claims
NovartisEntresto$142$13,22914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →